Attenuation of neuroleptic-induced extrapyramidal side effects by Kava special extract WS 1490.
We studied at 42 patients (17 female, 25 male) with different psychiatric diagnoses, who were pretreated by neuroleptics, the efficacy and tolerability of the Kava special extract WS 1490 on extrapyramidal side effects. In both patient and physician questionnaires as well as in the physician's global ratings, significant improvements were found for all extrapyramidal signs and symptoms recorded. The concomitant intake of WS 1490 was well tolerated by the patients. The findings of this observational study suggest that extrapyramidal side effects of neuroleptic drugs may be attenuated by Kava special extract WS 1490.
Boerner
Reinhard J
RJ
Psychiatric Hospital, Ludwig-Maximilians-University, Munich, Germany. r.boerner@christliches-krankenhaus-ev.de
Klement
Stephan
S
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D008517:Phytotherapy; D010936:Plant Extracts / Q000009:adverse effects / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000188:drug therapy*; D012563:Schizophrenia, Paranoid / Q000188:drug therapy*
D014150:Antipsychotic Agents; D010936:Plant Extracts; C488351:WS 1490